Jesse Hall
AstraZeneca
13 Papers
60 Citations
Jesse Hall is an academic researcher from AstraZeneca. The author has contributed to research in topics: Pharmacodynamics & Uric acid. The author has an hindex of 8, co-authored 10 publications.
Chat about Author
Papers
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
TL;DR: Single and multiple doses of verinurad were well tolerated, absorption was rapid, and exposure was dose proportional, and these data support further clinical evaluation of once-daily ver inurad as a treatment for gout.
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
Roy Fleischmann,Peter Winkle,Jeffrey N. Miner,Xiaohong Yan,Liz Hicks,Shakti Valdez,Jesse Hall,Sha Liu,Zancong Shen,Michael Gillen,Martha Hernandez-Illas +10 more
TL;DR: Serum pharmacodynamic data pooled across cohorts demonstrated maximum per cent decreases in serum urate (sUA) from baseline (Emax) at 7–12 hours after verinurad plus allopurinol treatment, and data support continued investigation of oral ver inurad in patients with gout.
33
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Masanari Shiramoto,Sha Liu,Zancong Shen,Xiaohong Yan,Amy Yamamoto,Michael Gillen,Yasushi Ito,Jesse Hall +7 more
TL;DR: Data from this Phase 2a, randomized, open-label study support continued investigation of oral verinurad in patients with gout, with data providing greater sUA lowering than febuxostat alone at the same dose (P < 0.001).
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
TL;DR: The combination of verinurad in combination with febuxostat resulted in greater reductions of serum urate than either drug alone and was well tolerated at the studied doses.
16
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Martin Kankam,Jesse Hall,Michael Gillen,Xiaojuan Yang,Zancong Shen,Caroline A. Lee,Sha Liu,Jeffrey N. Miner,Susan P. Walker,Vicki Clauson,David M. Wilson,Mai Nguyen +11 more
TL;DR: Despite decreased systemic exposure of allopur inol and oxypurinol in the presence of verinurad, the combination resulted in greater serum urate reduction compared with either drug alone and was well tolerated at the studied doses.
15